Recently, tumor-infiltrating lymphocytes (TIL), especially CD4+ T cells, cytotoxic CD8+ T cells, and γδ-T cells have been associated with clinical benefit and favorable prognosis in the tumor microenvironment [15,16,17]. The gene discussed is CD4; the disease is neoplasm.